Azenta Cuts FY26 Guidance to $603–621M, Extends Growth Plan to 2029
AZTA•Azenta reported Q2 revenue of $145 million, up 1% year-over-year, with organic revenue down 3% and adjusted EBITDA falling 39% to $8 million. It cut FY26 guidance to $603–621 million revenue, now forecasting a 0–125 bps EBITDA margin decline, and extended its long-range plan to 2029.
1. Q2 Financial Results
Azenta posted revenue of $145 million in Q2, up 1% year-over-year, while organic revenue declined 3% due to lower volumes and a cautious demand environment. Adjusted EBITDA fell 39% to $8 million and adjusted EBITDA margin dropped to 5.4%, and GAAP operating loss was $165.8 million driven by a $149 million goodwill impairment.
2. Revised FY26 Guidance
The company now expects full-year revenue of $603–621 million, down from prior growth targets of 3%–5%, with organic revenue projected at –2% to +1%. Adjusted EBITDA margin is forecast to decline by up to 125 basis points rather than expand, reflecting execution gaps and cost pressures.
3. Long-Range Plan Update
Azenta extended its long-range targets to 2029 from 2028, citing a disciplined approach in the current environment while maintaining confidence in its strategic priorities. Management plans to strengthen execution, reinforce operational discipline and improve visibility across the business.
4. Segment Performance
Sample Management Solutions delivered $81 million in revenue, up 2% year-over-year but with organic revenue down 3%, driven by lower core product sales. Multiomics contributed $64 million, flat year-over-year with a 2% organic decline in Sanger Sequencing partly offset by growth in next-generation sequencing and gene synthesis.
